KALA logo

Kala Pharmaceuticals (KALA) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

20 July 2017

Indexes:

Not included

Description:

Kala Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for eye diseases. They use a unique drug delivery technology to improve the effectiveness of medications, aiming to enhance patient outcomes and quality of life for those with vision-related conditions.

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Oct 21, 2022

Analyst ratings

Recent major analysts updates

15 Nov '24 HC Wainwright & Co.
Buy
19 Aug '24 Oppenheimer
Outperform
17 May '24 HC Wainwright & Co.
Buy
02 Apr '24 HC Wainwright & Co.
Buy
01 Apr '24 Oppenheimer
Outperform
17 Nov '23 HC Wainwright & Co.
Buy
11 Aug '23 HC Wainwright & Co.
Buy
10 May '23 HC Wainwright & Co.
Buy
01 May '23 HC Wainwright & Co.
Buy
12 Apr '23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
KALA
globenewswire.com27 November 2024

ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY on Wednesday, December 4, 2024 at 11:30 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, December 4, 2024.

KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade
KALA
zacks.com09 October 2024

KALA BIO (KALA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
KALA
Zacks Investment Research04 April 2024

The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
KALA
Zacks Investment Research13 November 2023

KALA BIO (KALA) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $19.25 per share a year ago.

Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know
Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know
Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know
KALA
Zacks Investment Research24 March 2023

The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

FAQ

  • What is the primary business of Kala Pharmaceuticals?
  • What is the ticker symbol for Kala Pharmaceuticals?
  • Does Kala Pharmaceuticals pay dividends?
  • What sector is Kala Pharmaceuticals in?
  • What industry is Kala Pharmaceuticals in?
  • What country is Kala Pharmaceuticals based in?
  • When did Kala Pharmaceuticals go public?
  • Is Kala Pharmaceuticals in the S&P 500?
  • Is Kala Pharmaceuticals in the NASDAQ 100?
  • Is Kala Pharmaceuticals in the Dow Jones?
  • When was Kala Pharmaceuticals's last earnings report?
  • When does Kala Pharmaceuticals report earnings?
  • Should I buy Kala Pharmaceuticals stock now?

What is the primary business of Kala Pharmaceuticals?

Kala Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for eye diseases. They use a unique drug delivery technology to improve the effectiveness of medications, aiming to enhance patient outcomes and quality of life for those with vision-related conditions.

What is the ticker symbol for Kala Pharmaceuticals?

The ticker symbol for Kala Pharmaceuticals is NASDAQ:KALA

Does Kala Pharmaceuticals pay dividends?

No, Kala Pharmaceuticals does not pay dividends

What sector is Kala Pharmaceuticals in?

Kala Pharmaceuticals is in the Healthcare sector

What industry is Kala Pharmaceuticals in?

Kala Pharmaceuticals is in the Biotechnology industry

What country is Kala Pharmaceuticals based in?

Kala Pharmaceuticals is headquartered in United States

When did Kala Pharmaceuticals go public?

Kala Pharmaceuticals's initial public offering (IPO) was on 20 July 2017

Is Kala Pharmaceuticals in the S&P 500?

No, Kala Pharmaceuticals is not included in the S&P 500 index

Is Kala Pharmaceuticals in the NASDAQ 100?

No, Kala Pharmaceuticals is not included in the NASDAQ 100 index

Is Kala Pharmaceuticals in the Dow Jones?

No, Kala Pharmaceuticals is not included in the Dow Jones index

When was Kala Pharmaceuticals's last earnings report?

Kala Pharmaceuticals's most recent earnings report was on 12 November 2024

When does Kala Pharmaceuticals report earnings?

The next expected earnings date for Kala Pharmaceuticals is 28 March 2025

Should I buy Kala Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions